Get started
Author

Aylin Sertkaya

Observed names: A Sertkaya, Sertkaya, Aylin
ORCID: 0000-0001-5830-649X
Observed ORCID: 0000-0001-5830-649X
OpenAlex ID: A5054354967
Key cost drivers of pharmaceutical clinical trials in the United States
2016 · Aylin Sertkaya, Hui-Hsing Wong, et al. · Clinical Trials · 417
Costs of Drug Development and Research and Development Intensity in the US, 2000-2018
2024 · Aylin Sertkaya, Trinidad Beleche, et al. · JAMA Network Open · 280
Estimated Cost of Developing a Therapeutic Complex Medical Device in the US
2022 · Aylin Sertkaya, Rebecca DeVries, et al. · JAMA Network Open · 77
PDF
Analytical Framework for Examining the Value of Antibacterial Products
2014 · Kevin Outterson, Aylin Sertkaya, et al. · bepress Legal Repository · 46
PDF
Food transportation safety: characterizing risks and controls by use of expert opinion.
2010 · Nyssa Ackerley, Aylin Sertkaya, et al. · Food Protection Trends · 46
An Expert Elicitation on the Effects of a Ban on Menthol Cigarettes and Cigars in the United States
2021 · David T Levy, Christopher J Cadham, et al. · Nicotine & Tobacco Research · 32
The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review
2021 · Christopher J. Cadham, Marie Knoll, et al. · Medical Decision Making · 15
An Analysis of the Proportion of the U.S. Population that Ingests Soil or Other Non-Food Substances
2011 · Naida Gavrelis, Aylin Sertkaya, et al. · Human and Ecological Risk Assessment An International Journal · 7
Top ten food safety problems in the United States food processing industry
2006 · Aylin Sertkaya, Ayesha Berlind, et al. · Food Protection Trends · 7
Assessing the state of antibacterial drug discovery through patent analysis
2023 · Aylin Sertkaya, J. Daniel McGeeney, et al. · International Journal of Antimicrobial Agents · 5
Promoting Antibacterial Drug Development: Select Policies and Challenges
2016 · Aylin Sertkaya, Amber Jessup, et al. · Applied Health Economics and Health Policy · 5
Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States
2018 · Aylin Sertkaya, Hui-Hsing Wong, et al. · American Journal of Infection Control · 4
Costs of Overly Broad Recalls
2025 · Nyssa Ackerley, Ayesha Berlind, et al. · Journal of Food Protection · 3
Measuring the First Mover Advantage in US Biosimilar Markets
2025 · J. Daniel McGeeney, Aylin Sertkaya, et al. · Value in Health · 2
Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer
2025 · Aylin Sertkaya, Zeid El-Kilani, et al. · PharmacoEconomics - Open
PDF
EE42 Value of Being the First Biosimilar Entrant
2024 · J.D. McGeeney, A Sertkaya, et al. · Value in Health
Works count: 19
Citation count: 946
H-index: 7
I10-index: 7
Year
Topic
Type